Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. It distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

Currency in USD	2025
Operating Income	1.26 Billion
Income Before Tax	1.27 Billion
Income Tax Expense	216.90 Million
Net Income	1.07 Billion
Eps	1.84
Epsdiluted	1.83
Weighted Average Shs Out	584.80 Million
Weighted Average Shs Out Dil	585.80 Million
Research And Development Expenses	1.08 Billion
Selling General And Administrative Expenses	2.09 Billion
Depreciation And Amortization	156.60 Million
Interest Expense	20.40 Million
Interest Income	N/A
Net Interest Income	-20.4 Million
Premiums Earned	N/A
Policyholder Benefits	N/A
Gross Profit	4.73 Billion
Ebitda	1.42 Billion

Edwards Lifesciences Corporation Annual Reports (10-K)